Nocutil (Desmopressin Acetate)

Desmopressin acetate mimics the natural hormone vasopressin and selectively activates V2 receptors in the kidney’s collecting ducts. This triggers a cascade that moves water channels to the cell surface, allowing more water to be reabsorbed and reducing urine output. It also stimulates endothelial cells to release von Willebrand factor and factor VIII, aiding blood clotting.

The appropriate dose of Nocutil is determined by the prescribing clinician based on the patient’s age, weight, renal function, and specific indication. Dosage may be adjusted during treatment to achieve the desired clinical response while monitoring for safety, especially serum sodium levels.

Safety data for desmopressin acetate in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers will evaluate individual circumstances before prescribing.

To request Nocutil, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and necessary import documentation.

Nocutil (desmopressin acetate) is a synthetic vasopressin analogue that offers a longer duration of action and selective V2‑receptor activity compared with natural vasopressin preparations. It is available as a nasal spray, which can be more convenient for some patients than injectable forms, and it also provides haemostatic benefits not seen with pure antidiuretic agents.

Nocutil should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the nasal spray from moisture and direct sunlight to maintain potency. Do not freeze the product, and keep it out of reach of children.

Nocutil is administered as a nasal spray. The prescribed number of sprays is delivered into one nostril, typically once or twice daily, depending on the indication and clinician’s instructions. Patients should avoid blowing their nose immediately after dosing to ensure optimal absorption.

The most serious risks include severe hyponatraemia, which can lead to seizures, cerebral oedema, or water intoxication. Patients should be monitored for signs of low sodium, such as headache, nausea, confusion, or weakness, and fluid intake may need to be restricted under medical supervision.

Nocutil is contraindicated in individuals with existing hyponatraemia, syndrome of inappropriate antidiuretic hormone secretion (SIADH), uncontrolled hypertension, or known hypersensitivity to desmopressin acetate. Caution is also advised for patients with severe renal impairment or those taking interacting medications that increase the risk of hyponatraemia.